Addendum
Addendum to Commission A13-05 (fidaxomicin)
Report documents
-
Addendum
Addendum to Commission A13-05 (fidaxomicin)
Press releases
Fidaxomicin: Data subsequently submitted by manufacturer prove added benefit
Now proof of minor added benefit in severe cases or recurrences of Clostridium difficile infections
Additional information
Federal Joint Committee (G-BA)
2013-07-04 A G-BA decision was published.
Project details
- Project no.
- A13-23
- Commission
- Commission awarded on 28.05.2013 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed